newsfilter
← Earnings
Earnings Releases·

Prelude Therapeutics — Third Quarter 2026 Earnings Summary

Prelude Therapeutics reported a net loss of $12.5 million for the third quarter ended September 30, 2026, with cash and equivalents totaling $142.7 million, extending its runway into the second quarter of 2028. The company initiated enrollment in a Phase 1 study for PRT13722, a selective KAT6A degrader for HR+ breast cancer, and entered a collaboration with Eli Lilly to evaluate this candidate in combination with abemaciclib and imlunestrant. Concurrently, enrollment continues for PRT12396, a mutant-selective JAK2V617F inhibitor for polycythemia vera and myelofibrosis, while preclinical data for an mCALR-targeted degrader antibody conjugate was accepted for presentation at the ASH 68th Annual Meeting.

Company
PRELUDE THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology